Aisleen Bennett1, Louisa Pollock2, Naor Bar-Zeev3, Joseph A Lewnard4, Khuzwayo C Jere2, Benjamin Lopman5, Miren Iturriza-Gomara6, Virginia E Pitzer7, Nigel A Cunliffe6. 1. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Institute of Infection and Immunity, St George's, University of London, London, UK. Electronic address: aisleen.bennett@liverpool.ac.uk. 2. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. 3. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; International Vaccine Access Center, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 4. School of Public Health, University of California Berkley, Berkley, CA, USA. 5. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 6. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; NIHR Health Protection Research Unit in Gastrointestinal Infections, University of Liverpool, Liverpool, UK. 7. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
Abstract
BACKGROUND: Rotavirus vaccine effectiveness is reduced among children in low-income countries. Indirect (transmission-mediated) effects of rotavirus vaccine might contribute to the total population effect of vaccination. We aimed to examine risk factors for transmission of rotavirus to household contacts in Blantyre, Malawi, and estimated the effectiveness of rotavirus vaccine in preventing transmission of infection to household contacts. METHODS: In this prospective household cohort study, we recruited children born after Sept 17, 2012, and aged at least 6 weeks (vaccine-eligible children) with acute rotavirus gastroenteritis and their household contacts, in four government health facilities in Blantyre, Malawi. Clinical data, a bulk stool sample, and 1-2 mL of serum were collected from case children at presentation. Clinical data and stool samples were also prospectively collected from household contacts over 14 days from presentation. A single stool sample was collected from control households containing asymptomatic children who were frequency age-matched to case children. Samples were tested for rotavirus using semi-quantitative real-time PCR and for anti-rotavirus IgA using a semi-quantitative sandwich ELISA. Risk factors for household transmission of rotavirus infection and clinical disease, including disease severity and faecal shedding density, were identified using mixed effects logistic regression. Vaccine effectiveness against transmission was estimated as 1 minus the ratio of secondary attack rates in vaccinated and counterfactual unvaccinated populations, using vaccine effectiveness estimates from the associated diarrhoeal surveillance platform to estimate the counterfactual secondary attack rate without vaccination. FINDINGS: Between Feb 16, 2015, and Nov 11, 2016, we recruited 196 case households (705 members) and 55 control households (153 members). Household secondary attack rate for rotavirus infection was high (434 [65%] of 665 individuals) and secondary attack rate for clinical disease was much lower (37 [5%] of 698). Asymptomatic infection in control households was common (40 [28%] of 144). Increasing disease severity in an index child (as measured by Vesikari score) was associated with increased risk of transmission of infection (odds ratio 1·17 [95% CI 1·06-1·30) and disease (1·28 [1·08-1·52]) to household contacts. Estimated vaccine effectiveness against transmission was 39% (95% CI 16-57). INTERPRETATION: Rotavirus vaccine has the potential to substantially reduce household rotavirus transmission. This finding should be considered in clinical and health economic assessments of vaccine effectiveness. FUNDING: Wellcome Trust, US National Institutes of Health, and US National Institute of Allergy and Infectious Diseases.
BACKGROUND: Rotavirus vaccine effectiveness is reduced among children in low-income countries. Indirect (transmission-mediated) effects of rotavirus vaccine might contribute to the total population effect of vaccination. We aimed to examine risk factors for transmission of rotavirus to household contacts in Blantyre, Malawi, and estimated the effectiveness of rotavirus vaccine in preventing transmission of infection to household contacts. METHODS: In this prospective household cohort study, we recruited children born after Sept 17, 2012, and aged at least 6 weeks (vaccine-eligible children) with acute rotavirus gastroenteritis and their household contacts, in four government health facilities in Blantyre, Malawi. Clinical data, a bulk stool sample, and 1-2 mL of serum were collected from case children at presentation. Clinical data and stool samples were also prospectively collected from household contacts over 14 days from presentation. A single stool sample was collected from control households containing asymptomatic children who were frequency age-matched to case children. Samples were tested for rotavirus using semi-quantitative real-time PCR and for anti-rotavirus IgA using a semi-quantitative sandwich ELISA. Risk factors for household transmission of rotavirus infection and clinical disease, including disease severity and faecal shedding density, were identified using mixed effects logistic regression. Vaccine effectiveness against transmission was estimated as 1 minus the ratio of secondary attack rates in vaccinated and counterfactual unvaccinated populations, using vaccine effectiveness estimates from the associated diarrhoeal surveillance platform to estimate the counterfactual secondary attack rate without vaccination. FINDINGS: Between Feb 16, 2015, and Nov 11, 2016, we recruited 196 case households (705 members) and 55 control households (153 members). Household secondary attack rate for rotavirus infection was high (434 [65%] of 665 individuals) and secondary attack rate for clinical disease was much lower (37 [5%] of 698). Asymptomatic infection in control households was common (40 [28%] of 144). Increasing disease severity in an index child (as measured by Vesikari score) was associated with increased risk of transmission of infection (odds ratio 1·17 [95% CI 1·06-1·30) and disease (1·28 [1·08-1·52]) to household contacts. Estimated vaccine effectiveness against transmission was 39% (95% CI 16-57). INTERPRETATION: Rotavirus vaccine has the potential to substantially reduce household rotavirus transmission. This finding should be considered in clinical and health economic assessments of vaccine effectiveness. FUNDING: Wellcome Trust, US National Institutes of Health, and US National Institute of Allergy and Infectious Diseases.
Authors: D I Bernstein; V E Smith; J R Sherwood; G M Schiff; D S Sander; D DeFeudis; D R Spriggs; R L Ward Journal: Vaccine Date: 1998-02 Impact factor: 3.641
Authors: Indrani Banerjee; Beryl Primrose Gladstone; Miren Iturriza-Gomara; James J Gray; David W Brown; Gagandeep Kang Journal: J Med Virol Date: 2008-10 Impact factor: 2.327
Authors: Shabir A Madhi; Nigel A Cunliffe; Duncan Steele; Desirée Witte; Mari Kirsten; Cheryl Louw; Bagrey Ngwira; John C Victor; Paul H Gillard; Brigitte B Cheuvart; Htay H Han; Kathleen M Neuzil Journal: N Engl J Med Date: 2010-01-28 Impact factor: 91.245
Authors: A Bennett; N Bar-Zeev; K C Jere; J E Tate; U D Parashar; O Nakagomi; R S Heyderman; N French; M Iturriza-Gomara; N A Cunliffe Journal: J Clin Microbiol Date: 2015-04-08 Impact factor: 5.948
Authors: Naor Bar-Zeev; Lester Kapanda; Jacqueline E Tate; Khuzwayo C Jere; Miren Iturriza-Gomara; Osamu Nakagomi; Charles Mwansambo; Anthony Costello; Umesh D Parashar; Robert S Heyderman; Neil French; Nigel A Cunliffe Journal: Lancet Infect Dis Date: 2015-01-29 Impact factor: 25.071
Authors: Ben Lopman; Yosselin Vicuña; Fabian Salazar; Nely Broncano; Matthew D Esona; Carlos Sandoval; Nicole Gregoricus; Michael D Bowen; Daniel Payne; Martiza Vaca; Martha Chico; Umesh Parashar; Philip J Cooper Journal: PLoS One Date: 2013-07-09 Impact factor: 3.240
Authors: Jonathan J Mandolo; Marc Y R Henrion; Chimwemwe Mhango; End Chinyama; Richard Wachepa; Oscar Kanjerwa; Chikondi Malamba-Banda; Isaac T Shawa; Daniel Hungerford; Arox W Kamng'ona; Miren Iturriza-Gomara; Nigel A Cunliffe; Khuzwayo C Jere Journal: Viruses Date: 2021-12-13 Impact factor: 5.048